Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Moderate Buy” by Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $21.38.

Several research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research note on Friday, November 15th. Canaccord Genuity Group restated a “buy” rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Morgan Stanley cut their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 13th. Wedbush reissued an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Finally, Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th.

Y-mAbs Therapeutics Trading Up 1.4 %

Shares of Y-mAbs Therapeutics stock opened at $10.56 on Thursday. Y-mAbs Therapeutics has a twelve month low of $5.31 and a twelve month high of $20.90. The stock has a market cap of $472.98 million, a price-to-earnings ratio of -19.56 and a beta of 0.68. The company has a fifty day moving average price of $13.69 and a 200 day moving average price of $12.84.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the previous year, the business posted ($0.18) earnings per share. Analysts forecast that Y-mAbs Therapeutics will post -0.64 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Thomas Gad sold 65,000 shares of the stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the sale, the insider now owns 97,681 shares of the company’s stock, valued at $1,315,763.07. This trade represents a 39.96 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 22.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of hedge funds have recently made changes to their positions in YMAB. State Street Corp increased its position in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after acquiring an additional 405,169 shares during the period. Caligan Partners LP increased its holdings in shares of Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares during the period. Geode Capital Management LLC raised its stake in shares of Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after purchasing an additional 47,846 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Y-mAbs Therapeutics by 15.7% in the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares during the period. Finally, Millennium Management LLC grew its position in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after buying an additional 67,233 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.